These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 3653052)
21. Comparative cognitive effects of carbamazepine and gabapentin in healthy senior adults. Martin R; Meador K; Turrentine L; Faught E; Sinclair K; Kuzniecky R; Gilliam F Epilepsia; 2001 Jun; 42(6):764-71. PubMed ID: 11422333 [TBL] [Abstract][Full Text] [Related]
22. Population pharmacokinetics of steady-state carbamazepine in Egyptian epilepsy patients. El Desoky ES; Sabarinath SN; Hamdi MM; Bewernitz M; Derendorf H J Clin Pharm Ther; 2012 Jun; 37(3):352-5. PubMed ID: 21883329 [TBL] [Abstract][Full Text] [Related]
23. Steady state pharmacokinetics of carbamazepine-phenobarbital interaction in patients with epilepsy. Sennoune S; Iliadis A; Bonneton J; Barra Y; Genton P; Mesdjian E Biopharm Drug Dispos; 1996 Mar; 17(2):155-64. PubMed ID: 8907722 [TBL] [Abstract][Full Text] [Related]
24. Fluctuations of carbamazepine concentrations during the day for two slow-release preparations. May T; Rambeck B Ther Drug Monit; 1989; 11(1):21-4. PubMed ID: 2911848 [TBL] [Abstract][Full Text] [Related]
25. Effects of gabapentin and carbamazepine on the EEG and cognition in healthy volunteers. Salinsky MC; Binder LM; Oken BS; Storzbach D; Aron CR; Dodrill CB Epilepsia; 2002 May; 43(5):482-90. PubMed ID: 12027908 [TBL] [Abstract][Full Text] [Related]
26. Criteria to assess in vivo performance and bioequivalence of generic controlled-release formulations of carbamazepine. Bialer M; Yacobi A; Moros D; Levitt B; Houle JM; Munsaka MS Epilepsia; 1998 May; 39(5):513-9. PubMed ID: 9596204 [TBL] [Abstract][Full Text] [Related]
27. Fluctuations in salivary carbamazepine and carbamazepine-10,11-epoxide concentrations during the day in epileptic children. Paxton JW; Aman MG; Werry JS Epilepsia; 1983 Dec; 24(6):716-24. PubMed ID: 6641647 [TBL] [Abstract][Full Text] [Related]
28. Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Baulac M; Rosenow F; Toledo M; Terada K; Li T; De Backer M; Werhahn KJ; Brock M Lancet Neurol; 2017 Jan; 16(1):43-54. PubMed ID: 27889312 [TBL] [Abstract][Full Text] [Related]
29. A comparative pharmacokinetic study of conventional and chewable carbamazepine in epileptic patients. Patsalos PN Br J Clin Pharmacol; 1990 May; 29(5):574-7. PubMed ID: 2350535 [TBL] [Abstract][Full Text] [Related]
30. The cognitive and psychomotor effects of remacemide and carbamazepine in newly diagnosed epilepsy. Wesnes KA; Edgar C; Dean AD; Wroe SJ Epilepsy Behav; 2009 Mar; 14(3):522-8. PubMed ID: 19111629 [TBL] [Abstract][Full Text] [Related]
31. Cognitive function and time-of-day variation in serum carbamazepine concentration in epileptic patients treated with monotherapy. Reinvang I; Bjartveit S; Johannessen SI; Hagen OP; Larsen S; Fagerthun H; Gjerstad L Epilepsia; 1991; 32(1):116-21. PubMed ID: 1985819 [TBL] [Abstract][Full Text] [Related]
32. Cognitive performances in newly referred patients with temporal lobe epilepsy: comparison with normal subjects in basal condition and after treatment with controlled-release carbamazepine. Gigli GL; Maschio M; Diomedi M; Placidi F; Silvestri G; Marciani MG Int J Neurosci; 1996 Nov; 88(1-2):97-107. PubMed ID: 9003968 [TBL] [Abstract][Full Text] [Related]
33. A comparative evaluation of pharmacokinetics of conventional and slow-release carbamazepine formulation in newly treated patients of epilepsy: a random evaluation. Nag D; Garg RK; Agarwal A J Assoc Physicians India; 1998 Feb; 46(2):185-8. PubMed ID: 11273108 [TBL] [Abstract][Full Text] [Related]
34. Influence of major antiepileptic drugs on attention, reaction time, and speed of information processing: results from a randomized, double-blind, placebo-controlled withdrawal study of seizure-free epilepsy patients receiving monotherapy. Hessen E; Lossius MI; Reinvang I; Gjerstad L Epilepsia; 2006 Dec; 47(12):2038-45. PubMed ID: 17201701 [TBL] [Abstract][Full Text] [Related]
35. Clinical monitoring during carbamazepine slow-release, once-daily monotherapy. Stefan H; Schäfer H; Kuhnen C; Schneider S Epilepsia; 1988; 29(5):571-7. PubMed ID: 3137020 [TBL] [Abstract][Full Text] [Related]
36. Carbamazepine extended-release capsules vs. oxcarbazepine: computer simulations of the effect of missed doses on drug plasma concentrations. Ahmad A; Garnett WR Curr Med Res Opin; 2005 Sep; 21(9):1363-8. PubMed ID: 16197654 [TBL] [Abstract][Full Text] [Related]
37. Double-blind crossover comparison of Tegretol-XR and Tegretol in patients with epilepsy. The Tegretol OROS Osmotic Release Delivery System Study Group. Neurology; 1995 Sep; 45(9):1703-7. PubMed ID: 7675230 [TBL] [Abstract][Full Text] [Related]
38. An international multicenter randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Saetre E; Perucca E; Isojärvi J; Gjerstad L; Epilepsia; 2007 Jul; 48(7):1292-302. PubMed ID: 17561956 [TBL] [Abstract][Full Text] [Related]
39. Effect of acute doses of controlled-release carbamazepine on clinical, psychomotor, electrophysiological, and cognitive parameters of brain function. van der Meyden CH; Bartel PR; Sommers DK; Blom M; Becker P; Erasmus S; Griesel D Epilepsia; 1992; 33(2):335-42. PubMed ID: 1547763 [TBL] [Abstract][Full Text] [Related]
40. The pharmacology of chewable versus regular carbamazepine in chronically treated children with epilepsy. Camfield P; Hwang P; Camfield C; Fraser A; Soldin S; al-Quadah AK Can J Neurol Sci; 1992 May; 19(2):204-7. PubMed ID: 1623447 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]